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Abstract
Purpose To compare supportive care costs associated
with second-line chemotherapy for advanced non-squa-
mous non-small cell lung cancer (advNS-NSCLC) in
Chinese patients.
Methods This retrospective cohort study included patients
receiving pemetrexed or docetaxel-based second-line che-
motherapy for advNS-NSCLC in four Chinese hospitals
from 2007 to 2012. The best matched pairs between
pemetrexed and other regimens were identified using
propensity score methods for head-to-head comparisons of
supportive care costs per treatment cycle. Linear regression
analyses were performed to rank log10 scale of supportive
care costs per treatment cycle associated with chemother-
apy by tumor response and hematologic toxicity.
Results 384 patients were included to create propensity
score-matched treatment groups for pemetrexed singlet
versus docetaxel singlet, platinum/pemetrexed, and plat-
inum/docetaxel, respectively. Pemetrexed singlet was
associated with significantly less supportive care costs per
treatment cycle than the two doublets (platinum/peme-
trexed: median difference -RMB 9,877, p = 0.003;
platinum/docetaxel: median difference -RMB 8,370,
p = 0.009; 1 RMB = 0.16 USD) but not docetaxel singlet
in matched patients. Of the four studied chemotherapy
regimens, pemetrexed singlet was associated with the
lowest log10 scale of supportive care costs per treatment
cycle in patients with tumor control (coefficient relative to
docetaxel singlet -1.049, p \ 0.001) or leukopenia (coef-
ficient relative to docetaxel singlet -0.991, p = 0.034).
Conclusion Pemetrexed singlet cost significantly less for
supportive care than pemetrexed or docetaxel-based dou-
blets when treating Chinese patients with AdvNS-NSCLC
in the second-line setting. Pemetrexed singlet was also
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associated with significantly less supportive care costs per
treatment cycle than docetaxel singlet in patients with
tumor control or leukopenia.
Key Points
Pemetrexed singlet was likely to be more cost-
effective than platinum/pemetrexed, having
comparable tumor response but significantly less
overall hospital costs in the second-line setting for
advanced non-squamous non-small cell lung cancer
(advNS-NSCLC).
Pemetrexed singlet could save enough supportive
care costs to completely offset the high drug
acquisition cost of pemetrexed when compared with
platinum/docetaxel doublet in the second-line setting
for advNS-NSCLC.
Pemetrexed singlet significantly saved supportive
care costs likely through reducing the severity of
hematologic toxicity when compared with docetaxel
singlet in the second-line setting for advNS-NSCLC.
Introduction
Following decades of industrialization in China, the annual
incidence and mortality rates of lung cancer in the country
have soared up to 53.6 and 45.6 % per 100,000 persons,
respectively, and lung cancer has replaced liver cancer as
the top cause of cancer-related death in China [1–3]. Due to
the challenges of early tumor detection [4–6], over half of
Chinese patients with lung cancer are diagnosed at
advanced stages [7]. Since non-small cell lung cancer
(NSCLC) accounts for over 80 % of all lung cancer cases
[8], systemic chemotherapy is the primary therapeutic
option for extending survival and control disease symptoms
in Chinese lung cancer patients [9].
Second-line chemotherapy was established a decade ago
after docetaxel was proven clinically efficacious in previ-
ously treated patients with advanced NSCLC [10]. More
recent clinical evidence suggested that the use of peme-
trexed, the second cytotoxic agent introduced into the
second-line setting in 2005 [11], likely resulted in better
disease response and less toxicity in patients with advanced
non-squamous NSCLC (advNS-NSCLC) [12, 13]. A recent
survey of physicians across 12 large cities in China sug-
gested that treatment with a platinum-based doublet with
pemetrexed or docetaxel was also frequently used in the
second-line setting for advanced NSCLC [9]. Even though
platinum-based doublets increase tumor response by
5–10 %, they cause significantly greater toxicity than sin-
glet-agent treatment [14]. This significant increase in
toxicity associated with doublet treatments is likely to
result in increased consumption of healthcare resources.
Thus, the main purpose of our study was to investigate the
impact of singlet and doublet treatments on hospital costs
for supportive care and thus clarify the appropriateness of
using platinum-based doublets in the second-line setting
for advNS-NSCLC from a perspective of resource use in
hospitals where chemotherapy is usually delivered to
Chinese patients.
Patients and Methods
Chemotherapy care in China is usually delivered in ter-
tiary-care hospital settings in order to manage the clinical
toxicity of chemotherapy and improve patient tolerance
[15]. Thus, we were able to use reliable hospital data to
conduct this retrospective cohort study to assess supportive
care costs associated with singlet or platinum-based dou-
blet treatment with pemetrexed or docetaxel in the second-
line setting for advNS-NSCLC in Chinese patients. The
four selected hospital settings included one tumor-spe-
cialized hospital and one general hospital in Beijing
[Chinese Academy of Medical Sciences Tumor Hospital
(CAMSTH), Xuanwu Hospital (XWH)] and in Changsha
[Hunan Provincial Tumor Hospital (HNPTH), Xiangya
Hospital (XYH)], respectively, in order to represent current
referral patterns and socioeconomic distribution in Chinese
patients with advNS-NSCLC [16]. This study was
approved by the ethics committees of the selected four
hospitals.
Patient Identification
Hospital admission registry databases in the four hospitals
were searched using the key words ‘‘lung cancer’’,
‘‘NSCLC’’, ‘‘non-squamous NSCLC’’, ‘‘adenocarcinoma
lung cancer’’, or ‘‘large-cell lung cancer’’ to identify pa-
tients hospitalized due to lung cancer. Because our study
was designed to identify eligible patients and retrospec-
tively collect data through electronic hospital information
systems, we defined our search period according to the
launch year of the electronic hospital information systems
in the four participating hospitals. The search periods
therefore differed according to hospital: 3 years for XYH
(1 January 2010 to 31 December 2012), 4 years for
CAMSTH (1 January 2009 to 31 December 2012), and
6 years for XWH and HNPTH (1 January 2007 to 31
December 2012). The identified patients were further
linked with their hospital records to review their tumor
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stage, histologic type, and history of chemotherapy for
further eligibility assessment. Our study included patients
with stage IIIb or IV biopsy-confirmed non-squamous
NSCLC who received singlet or platinum-based doublet
treatment (pemetrexed has been approved to treat advanced
NSCLC with cisplatin only in the second-line setting)
containing pemetrexed (given with supplementation of
folic acid and vitamin B12) or docetaxel as second-line
chemotherapy, which was defined as subsequent che-
motherapy after the failure of either first-line chemotherapy
or maintenance therapy. Our study excluded patients who
had no tumor histology information or had mixed squa-
mous and non-squamous histology. In order to control
possible confounding effects associated with target treat-
ment for epidermal growth factor receptor (EGFR) on the
treatment effects of chemotherapy, our study further
excluded patients receiving EGFR tyrosine kinase inhibitor
or EGFR monoclonal antibodies in the first-line setting or
as combination treatment in the second-line setting.
Data Extraction
For data extraction, the follow-up time was defined as the
period from the admission date of the first hospitalization
to the discharge date of the last hospitalization associated
with second-line chemotherapy, which ended upon treat-
ment discontinuation due to progressive disease or for
other reasons. Our study reviewed medical records asso-
ciated with the first hospitalization to extract patient
baseline characteristics including demographics, smoking
status, physical condition (assessed by Eastern Cooperative
Oncology Group, ECOG, performance status), marrow
function, tumor stage, tumor histologic subtype, and
metastatic status. Medical records associated with each
hospitalization during the follow-up were reviewed to ex-
tract admission and discharge date, dose and administration
schedule of chemotherapy, tumor response [assessed ac-
cording to the response evaluation criteria in solid tumors
(RECIST) [17]], and recorded adverse events (AEs) related
to chemotherapy (assessed by the Common Terminology
Criteria for Adverse Events with modification on anemia
[18]). Laboratory blood testing records associated with
each hospitalization were reviewed to confirm hematologic
AEs recorded in clinical notes. Hospital costs were ex-
tracted through review of billing summaries at hospital
discharge.
Outcome Measures
The primary outcome measures in our study were hospital
costs. Because hospital costs were classified differently in
the four hospitals, the hospital costs were re-classified as
chemotherapy drug costs (acquisition costs for
chemotherapeutic agents), non-chemotherapy drug costs
(acquisition costs for supportive medications treating
adverse events associated with chemotherapy, symptoms
related to advNS-NSCLC, or underlying co-morbidities),
and non-drug care costs (total hospital costs excluding
acquisition costs of all medications). Hospital supportive
care costs were defined as the combination of non-che-
motherapy drug costs and non-drug care costs. Since tumor
response and hematologic AEs likely had substantial
impact on hospital resource utilization, our study also
measured the best tumor response [classified as complete
response (CR), partial response (PR), stable disease (SD),
and progressive disease (PD) according to the definition of
RECIST] and the occurrences of hematologic AEs, including
neutropenia, leukopenia, anemia, and thrombocytopenia
during chemotherapy, in order to explore their relationship
with hospital costs. In addition, our study counted treat-
ment cycles which were needed for calculating hospital
costs per treatment cycle (HCTC).
Data Analyses
HCTC was calculated for each included patient by dividing
the aggregated hospital costs by the number of completed
treatment cycles. HCTC was presented in Renmingbi
(RMB), the Chinese currency with an exchange rate against
the US dollar of 1 RMM = US$0.16 in 2012. Propensity
score methods were used to create 1:1 matched treatment
groups for singlet treatment with pemetrexed versus
docetaxel, platinum/pemetrexed, and platinum/docetaxel,
respectively, for adjusted head-to-head comparisons on
best tumor response, hematologic AEs, and allocation of
HCTC. The matching condition was defined as a propen-
sity score difference of less than 0.01 between matched
pairs. The paired t test and McNemar’s test were used to
assess differences in continuous and dichotomous out-
comes between propensity score-matched treatment
groups. Because cost data are often skewed and it is not
appropriate to use means to describe the centre of cost data,
the Wilcoxon rank sign test was used to compare median
cost outcomes between propensity score-matched treatment
groups. Because conventional linear regression analysis is
typically not recommended to directly analyze skewed
hospital costs [19], the log10 scale of HCTC for supportive
care, which included non-chemotherapy drugs and non-
drug care, was used as the dependent variable in multiple
conventional linear regression analyses to rank the impact
of the studied chemotherapy regimens on supportive care
costs in patients stratified by their best tumor response and
hematologic AEs, respectively. Docetaxel singlet was used
as reference regiment in this linear regression analysis
because it is the first well established second-line che-
motherapy for NSCLC. SAS 9.2 was used to perform the
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data analysis, and statistical significance was defined as
p \ 0.05.
Results
According to the inclusion and exclusion criteria, 9,270
patients with a primary diagnosis of lung cancer were
identified and 8,886 patients were excluded (134 had no
pathological information, 181 with small cell lung cancer,
458 with squamous NSCLC, 314 with mixed with squa-
mous cell histology, 279 with tumor stage less than IIIB,
7,018 with no second-line chemotherapy, 287 with TKI or
EGFR monoclonal antibodies in the first- or second-line
settings, and 215 with treatment regimens not containing
pemetrexed or docetaxel). The final study cohort included
384 eligible patients, 46 receiving pemetrexed, 61 receiv-
ing docetaxel, 161 receiving platinum/pemetrexed (73
using cisplatin, 42 using nedaplatin, 37 using carboplatin,
five using lobaplatin, and four using oxaliplatin) and 116
receiving platinum/docetaxel (51 using cisplatin, 31 using
nedaplatin, 26 using carboplatin, four using lobaplatin, and
four using oxaliplatin). The patient identification processes
in the four hospitals are illustrated in Fig. 1.
Creating Propensity Score Matched Treatment Groups
The four study treatment groups had similar patient base-
line characteristics with a few exceptions. Patients receiv-
ing pemetrexed were significantly older than those
receiving platinum/pemetrexed (57.8 vs. 53.9 years,
p = 0.021) or platinum/docetaxel (57.8 vs. 53.4 years,
p = 0.019). Patients in the pemetrexed singlet treatment
group also had significantly higher neutrophilic granulo-
cyte counts (5.2 9 109/L) than the docetaxel singlet
treatment group (4.1 9 109/L, p = 0.017) or plat-
inum/docetaxel doublet (4.0 9 109/L, p = 0.003) and
significantly higher white blood cell count (WBC)
(7.8 9 109/L) than patients in the other three chemother-
apy regimens, respectively (docetaxel singlet: 6.4 9 109/L,
p = 0.008; platinum/pemetrexed doublet: 6.8 9 109/L,
p = 0.026: platinum/docetaxel doublet: 6.4 9 109/L,
p = 0.001). By adjusting for these unbalanced patient
baseline characteristics, propensity score methods created
matched treatment groups for pemetrexed versus docetaxel
singlet (17 pairs, propensity score: 0.3969 ± 0.2126 vs.
0.3966 ± 0.2125, p = 0.830), platinum/pemetrexed (33
pairs, propensity score: 0.2480 ± 0.1274 vs.
0.2472 ± 0.1260, p = 0.246), and platinum/docetaxel (29
pairs, propensity score: 0.2850 ± 0.1379 vs.
0.2855 ± 0.1370, p = 0.4933), respectively. The balance
of baseline characteristics between pemetrexed singlet and
platinum/pemetrexed doublet were significantly improved
with propensity score matching as the mean of the p values
associated with baseline characteristics increased by
81.8 % from 0.391 to 0.711 (Fig. 2a). However, the bal-
ance of baseline characteristics for pemetrexed versus
docetaxel singlet (Fig. 2b) and platinum/docetaxel
(Fig. 2c) showed only slight improvement.
Adjusted Comparisons on Best Tumor Response
and Hematologic Adverse Events
The number of treatment cycles associated with peme-
trexed singlet was similar to that for the two platinum-
based doublets but 2.4 cycles more than docetaxel singlet
(3.9 vs. 1.5 cycles, p = 0.193) in propensity score-matched
patients. Our study did not identify any cases of CR
associated with the four studied chemotherapy regimens in
the propensity score-matched patients. Further, adjusted
head-to-head comparisons did not show any significant
differences in best tumor response [relative risk (RR) for
PD ranged from 1.000, p = 1.000 when compared with
docetaxel to 2.335, p = 0.157 when compared with plat-
inum/docetaxel] or unknown tumor response (RR ranged
from 0.818, p = 0.480 when compared with plat-
inum/docetaxel to 0.842, p = 0.467 when compared to
platinum/pemetrexed) between pemetrexed and the other
three chemotherapy regimens. However, tumor response
information was lacking in 50 % or more of the matched
patients due to early treatment discontinuation (less than
two completed treatment cycles). When examining AEs,
pemetrexed singlet was associated with significantly lower
rates of neutropenia (6.1 vs. 30.3 %, RR 0.201, p = 0.021)
and anemia (39.4 vs. 69.7 %, RR 0.565, p = 0.004) com-
pared to platinum/pemetrexed and significantly lower rates
of neutropenia (3.5 vs. 24.1 %, RR 0.143, p = 0.034) and
leukopenia (3.5 vs. 34.5 %, RR 0.100, p = 0.007) com-
pared to platinum/docetaxel. The rate of any hematologic
AE was also significantly lower in the matched pemetrexed
group compared to the matched platinum/pemetrexed
group (42.4 vs. 75.8 %, RR 0.559, p = 0.005). Significant
differences in the occurrence of hematologic AEs were not
observed in the adjusted comparisons of pemetrexed and
docetaxel singlet treatments. The comparisons of best
treatment response and haematologic AEs between peme-
trexed singlet and the other three chemotherapy regimens
in propensity score-matched patients are summarized in
Table 1.
Adjusted Comparisons on the Allocation of Hospital
Costs per Treatment Cycle (HCTC)
Adjusted comparisons showed significantly higher median
HCTC for chemotherapy drugs with pemetrexed singlet
treatment compared to docetaxel (median difference RMB
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6,762, p \ 0.001) or platinum/docetaxel (median differ-
ence RMB 5,063, p \ 0.001). However, non-chemotherapy
drug costs (median difference -RMB 5,963, p = 0.015)
and non-drug care costs (median difference -RMB 1,189,
p = 0.022) were lower with pemetrexed singlet than with
platinum/docetaxel, which offset the increased HCTC for
chemotherapy drugs (median difference for total HCTC:
-RMB 3,213, p = 0.620). Pemetrexed singlet was asso-
ciated with cost savings for total HCTC (median difference
-RMB 11,351, p \ 0.001) in the adjusted comparison with
platinum/pemetrexed; pemetrexed singlet cost less for
chemotherapy drugs (median difference -RMB 5,819,
p = 0.124) and also cost significantly less for both non-
chemotherapy drugs (median difference –RMB 6,406,
p = 0.004) and non-drug care (median difference -RMB
1,798, p = 0.015). If taking non-chemotherapy drug costs
and non-drug care costs together as supportive care costs,
pemetrexed significantly saved HCTC for supportive care
when compared to platinum/pemetrexed (median differ-
ence -RMB 9,877, p = 0.003) or platinum/docetaxel
Fig. 1 Flowchart identifying eligible patients receiving second-line
chemotherapy for AdvNS-NSCLC in the four participating tertiary
care hospitals. AdvNS-NSCLC advanced non-squamous non-small cell
lung cancer, TKI tyrosine-kinase inhibitor, EGFR epidermal growth
factor receptor, CAMSTH Chinese Academy of Medical Sciences
Tumor Hospital, XWH Xuanwu Hospital, HNPTH Hunan Province
Tumor Hospital, XYH Xiangya Hospital
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(median difference -RMB 8,370, p = 0.009), respective-
ly, while supportive care costs did not differ between
pemetrexed and docetaxel singlet treatment. Comparisons
of the allocation of HCTC and supportive care costs per
treatment cycle between pemetrexed singlet and the other
three studied chemotherapy regimens in the propensity
score-matched patients are summarized in Table 2.
Impact of Chemotherapy Regimens on HCTC
for Supportive Care
Docetaxel was used as the reference regimen in order to
rank the impact of the four studied regimens on the log10
scale of HCTC for supportive care in multiple linear
regression analyses. Pemetrexed singlet was associated with
Fig. 2 Comparison of baseline patient characteristics between peme-
trexed singlet and the other three studied chemotherapy regimens
prior to and after propensity score matching. a Pemetrexed vs.
platinum/pemetrexed. b Pemetrexed vs. docetaxel. c Pemetrexed vs.
platinum/docetaxel. BMI body mass index, ECOG Eastern Coop-
erative Oncology Group
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the lowest log10 scale of HCTC for supportive care in 108
patients with tumor control (PR or SD) (coefficient -1.049,
p \ 0.001) (Fig. 3a), 88 patients experiencing leukopenia
(coefficient -0.991, p = 0.034) (Fig. 3b), and 202 patients
with any hematologic AEs (coefficient -0.467, p = 0.034)
(Fig. 3c). Non-significant trends also showed that peme-
trexed singlet was associated with the lowest common
logarithm of HCTC for supportive care in 160 patients
without any hematologic AEs (coefficient -0.407,
p = 0.079), 79 patients with neutropenia (coefficient
-0.973, p = 0.064), and 80 patients with thrombocytope-
nia (coefficient -0.638, p = 0.090).
Discussion
Our study is the first real-world study demonstrating that
platinum-based doublet treatment did not have a superior
tumor response but caused more toxicity and cost more
when compared with singlet treatment in the second-line
setting for advNS-NSCLC patients in China. Since tumor
response did not differ among the regimens, the substantial
hospital cost savings for supportive care associated with
pemetrexed compared to the platinum-doublets were per-
haps the result of the lower rates of occurrence of neu-
tropenia or leukopenia. Pemetrexed singlet also
significantly saved supportive care costs when compared to
docetaxel singlet in patients experiencing hematologic
AEs. This finding may suggest that the hematologic AEs
associated with pemetrexed singlet could be less severe and
require less hospital care for management.
Use of pemetrexed singlet resulted in fewer occurrences
of neutropenia and leukopenia and had lower associated
supportive care hospital costs, likely due to less use of
expensive granulocyte colony stimulating factor (G-CSF)
and antibiotics for treatment of these AEs and reduced
length of hospital stay for AE management [20]. For
example, we observed that the occurrence rates of neu-
tropenia associated with the two platinum-based doublets
were five to six times the neutropenia rate associated with
pemetrexed singlet in the propensity score-matched
patients (6.1 vs. 30.3 % for pemetrexed vs. platinum/
pemetrexed; 3.5 vs. 24.1 % for pemetrexed vs. plat-
inum/docetaxel). Thus, our results indicated substantial
hospital cost savings mainly with non-chemotherapy drugs
associated with pemetrexed singlet when compared to the
two platinum-based doublets. In addition, patients receiv-
ing chemotherapy regimens associated with a higher risk of
neutropenia or leukopenia are often given prophylactic
treatment and may be treated more aggressively to improve
treatment tolerance and prevent life-threatening infection
[21, 22]. Thus, the effects associated with prophylactic
treatment and aggressive AE management would be
accounted for in hospital costs of supportive care, which
included both medications and non-drug care for preven-
tion and management of hematologic AEs. Significantly
reduced supportive care costs associated with pemetrexed
singlet in patients experiencing leukopenia suggest that AE
Fig. 2 continued
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severity may have differed between pemetrexed and
docetaxel. The doubled median supportive care costs
associated with docetaxel compared with pemetrexed,
coupled with similar rates of leukopenia occurrence, might
suggest the need for more aggressive treatments for
leukopenia associated with docetaxel. We speculate that
use of more aggressive treatments for leukopenia associ-
ated with docetaxel treatment might have offset previously
Table 2 Head-to-head comparisons of the allocation of hospital costs per treatment cycle (HCTC) between pemetrexed and the other three
studied chemotherapy regimens in propensity score-matched patients (1 RMB ¥ = US$0.16)
Allocation of HCTC Median Median Median difference p value
Comparison Pemetrexed vs. platinum/pemetrexed
Matched pairs 33 pairs
Chemotherapy drug ¥11,034 ¥16,853 -¥5,819 0.124
Non-chemotherapy drug ¥3,094 ¥9,500 -¥6,406 0.004
Non-drug care ¥2,991 ¥4,788 -¥1,798 0.015
Total HCTC ¥20,247 ¥31,597 -¥11,351 0.005
HCTC for supportive care ¥5,054 ¥14,931 -¥9,877 0.003
Comparison Pemetrexed vs. docetaxel
Matched pairs 17 pairs
Chemotherapy drug ¥11,034 ¥4,272 ¥6,762 <0.001
Non-chemotherapy drug ¥2,475 ¥6,546 -¥4,071 0.225
Non-drug care ¥2,991 ¥4,022 -¥1,032 0.378
Total HCTC ¥21,548 ¥14,754 ¥6,793 0.487
HCTC for supportive care ¥5,054 ¥10,482 -¥5,428 0.225
Comparison Pemetrexed vs. platinum/docetaxel
Matched pairs 29 pairs
Chemotherapy drug ¥10,880 ¥5,817 ¥5,063 <0.001
Non-chemotherapy drug ¥2,793 ¥8,756 -¥5,963 0.015
Non-drug care ¥2,991 ¥4,179 -¥1,189 0.022
Total HCTC ¥17,381 ¥20,594 -¥3,213 0.620
HCTC for supportive care ¥5,321 ¥13,691 -¥8,370 0.009
Bold values represent p \ 0.05
Table 1 Head-to-head comparisons of best tumor response and occurrences of hematologicl adverse events (AEs) between pemetrexed and the
other three studied chemotherapy regimens in propensity score-matched patients
Treatment Pemetrexed vs. platinum/pemetrexed Pemetrexed vs. docetaxel Pemetrexed vs. platinum/docetaxel
Matched pairs 33 17 29
Outcome % % RR p value % % RR p value % % RR p value
Best tumor response
PR 12.1 12.1 1.000 1.000 11.8 5.9 2.000 0.564 13.8 10.4 1.322 0.706
SD 12.1 12.1 1.000 1.000 11.8 5.9 1.998 0.564 10.3 17.2 0.600 0.480
PD 27.3 18.2 1.500 0.439 23.5 23.5 1.000 1.000 24.1 10.3 2.335 0.157
Unknown 48.5 57.6 0.842 0.467 52.9 64.7 0.818 0.480 51.7 62.1 0.833 0.366
Hematologic AEs
Neutropenia 6.1 30.3 0.201 0.021 11.8 23.5 0.500 0.414 3.5 24.1 0.143 0.034
Leukopenia 9.1 21.2 0.429 0.103 11.8 23.5 0.500 0.414 3.5 34.5 0.100 0.007
Thrombocytopenia 15.2 21.2 0.717 0.480 23.5 5.9 4.000 0.180 20.7 27.6 0.750 0.564
Anemia 39.4 69.7 0.565 0.004 35.3 29.4 1.200 0.541 37.9 44.8 0.846 0.637
Any hematologic AE 42.4 75.8 0.559 0.005 47.1 52.9 0.889 0.416 44.8 69.0 0.650 0.071
Bold values represent p \ 0.05
PR partial response, SD stable disease, PD progressive disease, RR rate ratio
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Fig. 3 Impact of the four studied chemotherapy regimens (docetaxel
as reference) on the log10 scale of hospital costs per treatment cycle
for supportive care in patients with tumor control, leukopenia, or any
hematologic AEs during treatment. a Patients with tumor control (PR
or SD) (n = 108). b Patients with leukopenia (n = 88). c Patients
with any hematologic AEs (n = 202). AE adverse event, PR partial
response, SD stable disease, PD progressive disease, ECOG Eastern
Cooperative Oncology Group
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reported significant differences in the occurrence of grade 3
or 4 leukopenia between the two singlet treatments in the
clinical trial setting [11]. Our study also demonstrated that
supportive care costs associated with pemetrexed were
significantly reduced when compared with docetaxel in
patients who had PR or SD for their best tumor responses.
This finding may suggest that patients treated with
docetaxel singlet consumed more health resources for AE
management because supportive care costs for disease-
related symptoms should be much reduced in those patients
who responded to the two singlet treatments. Thus, this
finding further supports the earlier hypothesis of the con-
founding effects associated with AE management in our
study, and future cohort studies should make full adjust-
ment for AE management when assessing clinical toxicity
associated with chemotherapy in real-world clinical
settings.
Our study findings have significant implications for
clinical practices, health-policy making, and future research.
Our study has confirmed that supportive care costs are highly
sensitive to hematologic toxicity associated with che-
motherapy [15]. If we consider tumor response and less
clinical toxicity as health benefits, pemetrexed singlet would
likely be cost-effective compared to the two platinum-based
doublets by having comparable clinical effectiveness while
costing less for hospital care. Future cost-effectiveness
analysis is needed to confirm our speculation on the inap-
propriateness of treating advNS-NSCLC patients with
platinum-based doublets in the second-line setting [14]. As
the first real-world study estimating hospital costs associated
with second-line chemotherapy for advNS-NSCLC patients
in China, our study provides reliable cost data sources for
future cost-effectiveness analysis and budget impact ana-
lysis, which are increasingly used to support reimbursement
decision making in China. Our study also suggests that
supportive care costs could be used as an indicator for the
intensity of AE management that could indirectly reflect the
differences in toxicity profile between chemotherapy regi-
mens. Because real-world studies are usually associated
with uncontrolled confounders due to missing data, health
resource utilization associated with treatments should be
used as a supplementary outcome measure to confirm or
explain the observed clinical outcome differences in future
real-world studies.
Several limitations should be considered when inter-
preting the results of this study. Small sample size was a
major limitation in our study. Our study was only able to
create 17 propensity score-matched pairs for pemetrexed
versus docetaxel. With such a small sample size, our study
was unable to detect any significant differences in tumor
response, treatment toxicity, and supportive care costs be-
tween the two singlet treatments. Even though referral
patterns and geographic location were taken into account
for hospital selection to control for possible selection bias
associated with practices and social economic status, the
use of pemetrexed treatment was not evenly distributed in
the four hospitals, and the hospital settings were not ad-
justed in our data analyses due to the small sample size.
Since the cost of pemetrexed per treatment cycle was
twofold higher than docetaxel, patients receiving peme-
trexed treatments likely had a higher socioeconomic status,
which may cause overuse of health resources as richer
patients are likely to pursue more expensive care. Thus,
hospital costs associated with pemetrexed could be over-
estimated. Missing information was another major limita-
tion in our study. Tumor response assessment was lacking
in nearly half the included patients and our study was un-
able to collect information on AEs and medical care that
occurred outside of the study hospital settings. With
relatively small numbers of matched pairs, the missing
information might explain why our study was unable to
observe previously reported statistical differences in treat-
ment effectiveness and hematologic toxicity between
pemetrexed singlet and docetaxel singlet in the second-line
setting for advNS-NSCLC. Our study findings might have
limited generalizability as chemotherapy care could also be
delivered in outpatient settings in other countries. How-
ever, the chemotherapy care settings are unlikely to sig-
nificantly affect the trend of our findings because AE
management, the essential component of chemotherapy
care, should not be affected by care settings. Finally, our
study did not follow up patients for overall survival and
health resource utilization after second-line chemotherapy
and future cost-effectiveness analyses are still needed to
further confirm our study findings.
In summary, platinum/pemetrexed did not have superior
tumor response but increased hospital costs when com-
pared to pemetrexed singlet treatment in the second-line
setting for adv-NS NSCLC in Chinese patients. Peme-
trexed singlet treatment was able to save enough supportive
care costs to offset the high chemotherapy drug costs when
compared to platinum/docetaxel doublet. Pemetrexed sin-
glet treatment also cost significantly less for supportive
care than docetaxel singlet treatment in patients with tumor
control or leukopenia. The numerically lower occurrences
and lower severity of hematologic AEs in patients receiv-
ing pemetrexed singlet likely contributed to the saved
supportive care costs. Future cost-effectiveness analyses
taking into account overall survival benefits and health
resource utilization after second-line chemotherapy are
needed to confirm our study findings.
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